Related Experiment Video
Updated: Mar 30, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
Overview of Glucagon-like Peptide-1 Receptor Agonists
Laura Steadman1, Joan S Grant, Lucinda J Graven
1Laura Steadman, EdD, CRNP, is an Assistant Professor, School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama. Joan S. Grant, PhD, RN, is a Professor, School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama. Lucinda J. Graven, PhD, MSN, ARNP, is an Assistant Professor, College of Nursing, Florida State University, Tallahassee, Florida.
Abstract:
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C) levels, glucagon-like peptide-1 receptor agonists may be used. This article provides an overview of this class of agents and provides implications for home healthcare clinicians.
More Related Videos
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors
GPCRs Regulate Adenylyl Cylase Activity
Oral Hypoglycemic Agents: Biguanides and Glitazones

